GSK plc reports

Company location
London
GSK plc has filed 6,818 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 201-225 of 1,000 matching filings.

Per page
25
Current page
9
SC TO-C

SC TO-C

Filing date
20 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK TO ACQUIRE RAPT THERAPEUTICS

Filing date
20 Jan 2026
Reporting date
20 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING

Filing date
20 Jan 2026
Reporting date
20 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
16 Jan 2026
Reporting date
16 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Jan 2026
Reporting date
15 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Jan 2026
Reporting date
13 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EC APPROVAL OF SHINGRIX PFS

Filing date
07 Jan 2026
Reporting date
07 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN

Filing date
07 Jan 2026
Reporting date
07 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EXDENSUR APPROVED IN JAPAN

Filing date
06 Jan 2026
Reporting date
06 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
05 Jan 2026
Reporting date
05 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
05 Jan 2026
Reporting date
05 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA

Filing date
05 Jan 2026
Reporting date
05 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US

Filing date
23 Dec 2025
Reporting date
23 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
22 Dec 2025
Reporting date
22 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
22 Dec 2025
Reporting date
22 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
19 Dec 2025
Reporting date
19 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
18 Dec 2025
Reporting date
18 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA

Filing date
17 Dec 2025
Reporting date
17 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
17 Dec 2025
Reporting date
17 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL

Filing date
16 Dec 2025
Reporting date
16 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
16 Dec 2025
Reporting date
16 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-37627

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filing date
15 Dec 2025
Reporting date
11 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
15 Dec 2025
Reporting date
15 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION

Filing date
12 Dec 2025
Reporting date
12 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD

Filing date
12 Dec 2025
Reporting date
12 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .